Complement activation determines the therapeutic activity of rituximab in vivo

Journal of Immunology

Volumn 171, Issue 3, 2003, Pages 1581-1587

  Di Gaetano, Nicola ^a   Cittera, Elena ^a   Nota, Rachele ^a   Vecchi, Annunciata ^a   Grieco, Valeria ^b   Scanziani, Eugenio ^b   Botto, Marina ^c   Introna, Martino ^a   Golay, Josée ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENTARY DNA; DACLIZUMAB; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG MECHANISM; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KNOCKOUT MOUSE; LIVER; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR GROWTH;

EID: 0042346042     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.3.1581     Document Type: Article

References (44)

1. Carter, P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1:118.
2. White, C. A., R. L. Weaver, and A. J. Grillo-Lopez. 2001. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:125.
3. Reff, M. E., C. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
4. McLaughlin, P., C. A. White, A. J. Grillo-Lopez, and D. G. Maloney. 1998. Clinical status and optimal use of rituximab for B cell lymphomas. Oncology 12:1763.
5. Coiffier, B., E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van den BNeste, G. Salles, P. Gaulard, et al. 2002. CHOP chemotherapy plus rituximab compared to chop alone in elderly patients with diffuse large B cell lymphoma. N. Engl. J. Med. 346:235.
6. Foran, J. M., A. Z. Rohatiner, D. Cunningham, R. A. Popescu, P. Solal-Celigny, M. Ghielmini, B. Coiffier, P. W. Johnson, C. Gisselbrecht, F. Reyes, et al. 2000. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18:317.
7. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383.
8. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazzari, G. M. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900.
9. Belosillo, B., N. Villamor, A. Lopez-Guillermo, S. Marcé, J. Esteve, E. Campo, D. Colomer, and E. Montserrat. 2001. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98:2771.
10. Van der Kolk, L. E., A. J. Grillo-Lopez, J. W. Baars, C. E. Hack, and M. H. van Oers. 2001. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115:807.
11. + cells by rituximab. Blood 101:1071.
12. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγIIIa gene. Blood 99:754.
13. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443.
14. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644.
15. Pedersen, I. M., A. M. Buhl, P. Klausen, C. H. Geisler, and J. Jurlander. 2002. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99:1314.
16. Byrd, J. C., S. Kitada, I. W. Flinn, J. L. Aron, M. Pearson, D. Lucas, and J. C. Reed. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99:1038.
17. Introna, M., A. Barbui, F. Bambacioni, C. Casati, G. Gaipa, G. M. Borleri, S. Bernasconi, T. Barbui, J. Golay, A. Biondi, and A. Rambaldi. 2000. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11:611.
18. 1 phase of the cell cycle. J. Immunol. 135:3795.
19. Tanaka, T., F. Kitamura, Y. Nagasaka, K. Kuida, H. Suwa, and M. Miyasaka. 1993. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J. Exp. Med. 178:1103.
20. Pruijt, J. F. M., P. Verzaal, R. van Os, E. F. M. de Kuijf, M. L. J. van Schie, A. Mantovani, A. Vecchi, I. J. D. Lindley, R. Willemze, S. Starckx, et al. 2002. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc. Natl. Acad. Sci. USA 99:6228.
21. Botto, M., M. C. Dell'Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry, M. Loos, P. P. Pandolfi, and M. J. Walport. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56.
22. Garlanda, C., E. Hirsch, S. Bozza, A. Salustri, M. De Acetis, R. Nota, A. Maccagno, F. Riva, B. Bottazzi, G. Peri, et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182.
23. Arase, H., T. Suenaga, N. Arase, Y. Kimura, K. Ito, R. Shiina, H. Ohno, and T. Saito. 2001. Negative regulation of expression and function of FcγRIII by CD3ζ in murine NK cells. J. Immunol. 166:21.
24. Ding, L., M. Sunamura, T. Kodama, J. Yamauchi, D. G. Duda, H. Shimamura, H. Shibuya, K. Takeda, and S. Matsuma. 2001. In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. Br. J. Cancer 85:431.
25. + T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 92:561.
26. Rose, A. L., B. E. Smith, and D. G. Maloney. 2002. Glucocorticoids and rituximab in vitro: synergistic direct anti-proliferative and apoptotic effects. Blood 100:1765.
27. Gazzano-Santoro, H., P. Ralph, T. C. Ryskamp, A. B. Chen, and V. R. Mukku. 1997. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J. Immunol. Methods 202:163.
28. Van der Kolk, L. E., M. de Haas, A. J. Grillo-Lopez, J. W. Baars, and M. H. van Oers. 2002. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16:693.
29. Valerius, T., R. Repp, T. P. de Wit, S. Berthold, E. Platzer, J. R. Kalden, M. Gramaski, and J. G. van de Winkel. 1993. Involvement of the high affinity receptor for IgG (FcγRI: CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931.
30. Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, et al. 2002. FcγRI (CD64.) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16:391.
31. Runyon, K., K. Lee, K. Zuberek, M. Collins, J. P. Leonard, and K. Dunussi-Joannopoulos. 2001. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood 97:2420.
32. Miwa, T., L. Zhou, B. Hilliard, H. Molina, and W. C. Song. 2002. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 99:3707.
33. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045.
34. Di Gaetano, N., Y. M. Xiao, E. Erba, R. Bassan, A. Rambaldi, J. Golay, and M. Introna. 2001. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114:1.
35. Weiner, G. J. 2003. Rituximab: complementary mechanisms of action. Blood 101:788.
36. Anderson, D. R., A. Grillo-Lopez, C. Vams, K. S. Chambers, and N. Hanna. 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25:705.
37. Keating, M. J., S. O'Brien, and M. Albitar. 2002. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin. Oncol. 29:70.
38. Manches, O., G. Lui, L. Chaperot, R. Gressin, J. P. Molens, M. C. Jacob, J. J. Sotto, D. Leroux, J. C. Bensa, and J. Plumas. 2003. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949.
39. Barrington, R., M. J. Zhang, P. Fischer, and M. C. Carroll. 2001. The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180:5.
40. Gorter, A., and S. Meri. 1999. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20:576.
41. Van Spriel, A. M., H. H. van Ojik, A. Bakker, M. J. H. Jansen, and J. J. G. van de Winkel. 2003. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101:253.
42. Shushakova, N., J. Skokowa, J. Schulman, U. Baumann, J. Zwirner, R. E. Schmidt, and J. E. Gessner. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J. Clin. Invest. 110:1823.
43. Trcka, J., Y. Moroi, R. A. Clynes, S. M. Glodberg, A. Bergtold, M.-A. Perales, M. Ma, C. R. Ferrone, M. C. Carroll, J. V. Ravetch, and A. N. Houghton. 2002. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 16:861.
44. Idusogie, E. E., P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2571.